The new stock pricing | Zhiyun Health received a subscription of 7.89 times, with a price of HK$30.50 per share.

On July 5th, Futu News announced on Tuesday.$CLOUDR (09955.HK)$Announced that the company issued 19 million shares at a price of HK$30.50 per share, in board lots of 100 shares, expected to be listed on July 6th.

In the public offering stage, Zhilin Health received subscriptions at 7.89 times the offering, with the final number of shares allocated to the public offering at 1.9 million shares, representing approximately 10% of the total shares offered (before any exercise of the over-allotment option). A total of 8629 valid applications were received, with a 50.00% allotment rate.

In addition, the international offering was oversubscribed, with the final number of shares offered at 17.1 million, equivalent to approximately 90% of the total shares offered (before any exercise of the over-allotment option). Futu News has compiled the relevant data in the table below:

According to the prospectus,Zhilin Health provides medical supplies and SaaS products to hospitals and pharmacies, digital marketing services to pharmaceutical companies, online consultations and prescriptions for patients, all centered around chronic disease management.Zhilin Health expects to continue generating the majority of its revenue by selling medical supplies to hospitals and pharmacies in the near future.

Zhilin Health aims to lead the digitized chronic disease management market in China by providing solutions to all major participants in the medical value chain, including hospitals, pharmacies, pharmaceutical companies, patients, and doctors. According to Frost & Sullivan report, based on the deployment of hospital and pharmacy SaaS in China as of December 31, 2021, and the number of online prescriptions issued through Zhilin Health as of 2021, Zhiyun Health is the largest provider of digital chronic disease management solutions in China.。

Zhiyun Health provides in-hospital solutions, pharmacy solutions, and personal chronic disease management solutions.In-hospital solutionsIncluding sales of medical instruments, consumables, pharmaceuticals, hospital saas, and digital marketing services for pharmaceutical companies, mainly selling medical instruments and consumables.Pharmacy solutionsIncluding sales of medical instruments, consumables, pharmaceuticals, and other categories of commodities, as well as Zhiyun Health's pharmacy saas. The medical supplies sold are mainly related to chronic disease management, while the pharmacy SaaS product enables pharmacies to have the ability to prescribe and dispense medication online.Personal chronic disease management solutionsConnect doctors with patients, realize outpatient consultations and prescription issuance for chronic disease management outside the hospital.

Financial SituationIn terms of total revenue, the company's revenue for 2019-2021 was 0.524 billion, 0.839 billion, and 1.757 billion RMB, with a compound annual growth rate of 83.02% from 2019 to 2021; the net losses for the same period were 0.569 billion, 2.751 billion, and 4.021 billion RMB.

Industry FocusDriven by favorable policies and continuous technological advancements, different sectors of the medical and health industry are experiencing a significant acceleration in digitalization in China. This has led to a rapid growth in China's digital health and healthcare market, with the entire market expected to reach 1511.6 billion RMB by 2025. The compound annual growth rate from 2020 to 2025 is projected at 37.5%, further reaching 4165.2 billion RMB by 2030. The compound annual growth rate from 2025 to 2030 is estimated at 22.5%.

145K Views